Avera Cancer Sequencing and Analytics Protocol (ASAP)

Launched by AVERA MCKENNAN HOSPITAL & UNIVERSITY HEALTH CENTER · Nov 18, 2021

Keywords

ClinConnect Summary

The Avera Cancer Sequencing and Analytics Protocol (ASAP) is a clinical trial aimed at understanding the genetic features of different types of cancer, including breast, lung, colon, and other cancers. The study will analyze tissue and blood samples from participants to identify the genetic changes that may lead to cancer or precancerous conditions. This research will help improve cancer diagnosis, treatment, and prevention strategies. Additionally, participants will undergo hereditary cancer testing, which can provide important information for their families about cancer risks.

To participate in this study, you must be at least 18 years old and either undergoing evaluation for a precancerous condition or have a cancer diagnosis. If you join the trial, you will have your health information linked to the genetic data collected, which will help researchers learn more about cancer and potentially improve future treatments. Participants will also be asked if they would like to store their samples for future research. The study is currently recruiting and welcomes people of all genders.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Must be at least 18 years of age
• • Must be undergoing a workup or being followed for a premalignant condition or have a diagnosis of cancer
• • Must voluntarily sign and understand the most current IRB-approved consent form prior to study participation
• Exclusion Criteria:
• • Participants incapable of understanding the items listed in the consent form and process
• • Participants with a history of or known psychiatric illness deemed unable to consent or adhere to study requirements